Hasan Ahmad, MD
Interventional Cardiology · Valhalla, NYNPI 1255478517
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $17,124 of the $25,147 with a category attached, or 68.1%. 20 manufacturers reported payments, led by Edwards Lifesciences at 51.8% of the total.
Across 215 payments — averaging $116.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$13K
- Abbott$3K
- Medtronic$2K
- Angiodynamics, Inc.$2K
- Boston Scientific$2K
- Abiomed$553
- plus $2K from 14 others
Across 22 payments — averaging $20,683 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$455K
What the payments were for
- Travel & lodging$17,12468%
- Food & beverage$8,02432%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 47 | $13,025 |
| Abbott | 29 | $3,149 |
| Medtronic(2 entities) | 33 | $2,485 |
| Angiodynamics, Inc. | 8 | $2,188 |
| Boston Scientific | 18 | $1,736 |
| Abiomed | 11 | $553 |
| Novartis | 27 | $320 |
| Chiesi USA, Inc. | 19 | $304 |
| Inari Medical, Inc. | 7 | $298 |
| Shockwave Medical, Inc | 2 | $221 |
| Stryker | 3 | $191 |
| Endologix LLC | 1 | $150 |
| Biocomposites Inc | 1 | $145 |
| W. L. Gore & Associates, Inc. | 2 | $132 |
| United Therapeutics Corporation | 1 | $118 |
| Philips North America LLC | 2 | $56 |
| Cardiva Medical, Inc. | 1 | $24 |
| Penumbra, Inc. | 1 | $21 |
| Recor Medical Inc | 1 | $19 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$12,092
- AngioVac$1,480
- MitraClip$1,220
- TRICLIP$1,215
- COREVALVE EVOLUT R$970
- WATCHMAN Access System$718
- AlphaVac$624
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$535
- Watchman$437
- Impella$367
- CoreValve Evolut$247
- Abre$197
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$177
- Torus Stent Graft System$150
- ENDOCROSS Device$150
- LUX-Dx Insertable Cardiac Monitor$146
- Stimulan$145
- FLOWTRIEVER CATHETER, S$141
- CT THROMBECTOMY SYSTEM KIT$141
- CLOTTRIEVER BOLD CATHETER$136
How this compares
$25,147 in reported general payments places this provider in the 70th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $113,678 |
| EntrestoSacubitril/Valsartan | 66 | $106,345 |
| FarxigaDapagliflozin Propanediol | 49 | $58,898 |
| XareltoRivaroxaban | 22 | $23,349 |
| Repatha SureclickEvolocumab | 28 | $16,039 |
| Metoprolol Succinate | 191 | $3,074 |
| Atorvastatin Calcium | 209 | $3,058 |
| Ezetimibe | 59 | $1,941 |
| Rosuvastatin Calcium | 108 | $1,467 |
| Lisinopril | 154 | $1,204 |
| Carvedilol | 96 | $965 |
| ClopidogrelClopidogrel Bisulfate | 104 | $856 |
| Amlodipine Besylate | 107 | $729 |
| Chlorthalidone | 30 | $725 |
| Nitroglycerin | 21 | $662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $320 | $106,34566 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Valhalla
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Evan ShlofmitzRoslyn$951K
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- David CohenRoslyn$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.